Full-Time

Manufacturing Supervisor

Operations, Lilly Medicine Foundry

Lilly USA

Lilly USA

10,001+ employees

Global pharmaceutical company developing medicines

Compensation Overview

$35.33 - $57.12/hr

+ Bonus

No H1B Sponsorship

Indianapolis, IN, USA + 1 more

More locations: Whitestown, IN, USA

In Person

Initial site in Indianapolis, IN during pre-startup; 10% travel; rotating 12-hour shifts.

Category
Medical, Clinical & Veterinary (1)
Required Skills
REST APIs
Requirements
  • HS Diploma/GED
  • API supervisory experience required
  • 5+ years experience directly supporting/supervising a manufacturing operation, preferably in a GMP and/or chemical processing environment
  • Qualified applicants must be authorized to work in the United States on a full-time basis. Lilly will not provide support for or sponsor work authorization or visas for this role, including but not limited to F-1 CPT, F-1 OPT, F-1 STEM OPT, J-1, H-1B, TN, O-1, E-3, H-1B1, or L-1.
Responsibilities
  • Overseeing the safety and quality of products and compliance of rigs and buildings.
  • Assist in delivering the production schedule and supervise process operators in the Lilly Medicine Foundry business.
  • Provide initial management responses to events and manage employee relations for all shift personnel.
  • Be part of the Foundry production and building management teams, sharing responsibility for meeting production targets.
  • Enforce adherence to compliance requirements (safety, quality, and environmental) and appropriately escalating any adverse events.
  • Overseeing operation of processes and equipment according to batch records, user manuals, design parameters, standard operating procedures, and work instructions to meet production schedule.
  • Oversee monitoring, testing, cleaning, and operation of area equipment and systems. Ensure all systems are in good operating condition and maintained per applicable requirements.
  • Serve as a key leader for site safety culture, promoting compliant operations and positive safety behaviors. Lead by example and promote accountability at all levels.
  • Provide technical leadership for troubleshooting and reaction to process upsets, integrating operator input and escalating as appropriate.
  • Follow all applicable procedures for safety event reporting and documentation. This includes following appropriate spill response procedures, escalation of issues, and initiating Emergency Response procedures as needed.
  • Follow all applicable procedures for quality event reporting and documentation. This includes entry/completion of GMP deviation records, interface with Quality Assurance, and escalation of issues as needed.
  • Oversee communication between shifts regarding the status of area operations and addressing any issues/problems that have occurred at shift passover.
  • Participating in daily shift huddles/meetings to understand and set expectations for daily operational goals.
  • Lead and make assignments for building and area operations such as safety audits, procedure coordination, housekeeping, and continuous improvement projects.
  • Ensure all area personnel follow cGMP practices, safe work habits, plant dress code, hygiene standards, and housekeeping requirements unique to the work area and job classification.
  • Enforce use of specified company-supplied personal protective equipment (PPE) (e.g., hair and beard coverings, lab coats or gowns, safety shoes, safety glasses, hard hats, etc.) as required.
  • Responsible for the effective deployment of operators to meet production schedules, maintaining adequate cover for Emergency Response Teams, managing holiday and overtime levels across process and production operators, timecard and coding for process operators.
  • Responsible for individuals’ performance on shift, managing employee relations and completing annual performance management processes.
  • Ensure that all shift members are appropriately trained, and that operating procedures and training material are available and current.
  • Partner with area Associate Director to understand Foundry strategy and future production needs. Represent and support this strategy in conversations with shift members.
  • Manage collaborations, both formal and informal, between the shift and functional support groups such as maintenance, engineering, analytical laboratory, and Technical Support.
Desired Qualifications
  • Bachelor’s or Associate's Degree in science, engineering, or technical field
  • Previous experience in facility/area start-up environments
  • Previous experience in pharmaceutical manufacturing operations
  • Demonstrated leadership experience
  • Skills in providing/receiving feedback and creating employee development plans
  • Basic computer skills (desktop software) are required
  • Solid understanding of FDA guidelines and cGMP requirements
  • Knowledge of lean manufacturing principles
  • Ability to work with a team, make independent decisions, and influence diverse groups
  • Ability to instill teamwork within the shift and demonstrate key interpersonal skills
  • Ability to communicate verbally and in writing to various audiences, particularly one-on-one coaching and feedback with direct reports
  • Excellent interpersonal, written and oral communication skills
  • Strong organizational skills and ability to handle and prioritize multiple requests
  • Strong technical proficiency and ability to train and mentor others

Lilly is a global pharmaceutical company that discovers, develops, and sells prescription medicines to improve health outcomes. It grows its portfolio through extensive research and development, then manufactures and distributes drugs worldwide to healthcare providers who prescribe them to patients. Lilly’s products span diabetes, cancer, immunology, pain management, and other serious conditions, including diabetes treatments tirzepatide and dulaglutide. The company emphasizes safety, efficacy, and ethical practices, and protects its products from counterfeiting while partnering with organizations such as Team USA. Its approach relies on rigorous R&D, strong manufacturing, and a global distribution network to bring medicines to patients. Lilly’s goal is to help people live better lives by delivering reliable medical solutions through a global, ethical, and quality-focused operation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Indianapolis, Indiana

Founded

1876

Simplify Jobs

Simplify's Take

What believers are saying

  • Mounjaro and Zepbound generated $12.8 billion in Q1 2026 sales.
  • Lilly raised 2026 revenue guidance to $82.0 billion-$85.0 billion.
  • EBGLYSS's eight-week maintenance dosing strengthens Lilly's dermatology franchise.

What critics are saying

  • Novo Nordisk's GLP-1 franchise intensifies pricing pressure and payer preferencing against Lilly.
  • Medicare GLP-1 Bridge prior authorization can slow obesity drug uptake.
  • Germany's reimbursement reforms already forced a major Alzey investment reduction.

What makes Lilly USA unique

  • Lilly pairs blockbuster metabolic drugs with rapid pipeline expansion and capital allocation.
  • Its U.S.-based headquarters in Indianapolis anchors a global, research-driven pharmaceutical platform.
  • The company combines medicines with partnerships like Abridge, AlzeCure, and Ascidian.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Lilly USA who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Flexible Work Hours

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-5%

2 year growth

-5%
The Lebanon Reporter
May 7th, 2026
Lilly invests additional $4.5B in LEAP district, opens first genetic medicine facility

Eli Lilly has announced an additional $4.5 billion investment in its Lebanon, Indiana facilities, bringing its total investment in the LEAP Innovation and Research district to $21 billion. The company opened its first Advanced Therapies site on Wednesday, marking the first operational facility in the 9,000-acre LEAP district. The new funding will support Lilly's Advanced Therapies laboratory and an active pharmaceutical ingredient facility expected to open in 2027. The Advanced Therapies site is Lilly's first dedicated genetic medicine manufacturing facility, focusing on molecular-level research for diseases including Alzheimer's, Parkinson's and ALS. Lilly is developing three facilities across 800 acres in LEAP, including a Medicine Foundry. The Advanced Therapies facility aims to accelerate delivery of breakthrough genetic medicines to patients.

AI Software Services
May 5th, 2026
Unlocking AI innovation in finance medicine and music.

Unlocking AI innovation in finance medicine and music. Published on May 05, 2026 GENETIC MEDICINE REVOLUTION: AI AND BIOTECH JOIN FORCES. In a groundbreaking partnership, Lilly and AI-driven Profluent Bio are teaming up in a deal worth up to $2.25 billion to develop advanced DNA editing tools. Their goal? To create precise treatments for genetic conditions that currently lack effective solutions, using innovative AI models to design enzymes that can target multiple mutations in the genome. This collaboration aims to unlock the "holy grail" of genetic medicine through kilobase-scale DNA editing. This matters because it could transform how AI Software Services treat genetic diseases, offering hope to millions who suffer from conditions deemed untreatable. The tools being developed are likely to be accessible, lowering barriers to entry in a field that has traditionally been expensive and exclusive. Imagine a startup that provides a platform for creators and developers to access these AI-driven genetic editing tools, enabling them to innovate and create personalized therapies. This could attract investors eager to support the next wave of medical breakthroughs!

The Economic Times
May 4th, 2026
French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly.

French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly. The ANSM fined Novo Nordisk 783,838 euros regarding adverts for Wegovy and also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." * Updated On May 4, 2026 at 05:54 PM IST Paris: France's medicine safety agency ANSM said Monday it had imposed fines on pharmaceutical firms Novo Nordisk and Eli Lilly over their advertising campaigns on obesity. The agency fined on Novo Nordisk France 1.78 million euros ($2.08 million) - a million relating to adverts promoting its Saxenda drug and 783,838 euros regarding adverts for Wegovy weight management medication for treating obesity. The ANSM also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." French laws prohibit any advertising to the general public of the treatments. The national medicines regulator said that the fines aimed to "prevent any communication likely to promote the use of drug treatment as the principal response to obesity, to encourage the public to request this treatment from a healthcare professional or seek to obtain it themselves." Event. * Fri, 24 Jul 2026 * Le Meridien, Hyderabad The ANSM said the advertising campaigns were "likely to mislead the public in a context marked by extensive media coverage" as well as what it termed growing inappropriate use of medications which activate certain hormones in order notably to reduce appetite,and aid weight loss. In a statement to AFP, Novo Nordisk France said it "strongly contests" the ANSM's finding, adding it is "exploring all possible appeal avenues against this decision". Lilly France said it noted ANSM's decision, while stating it believes its awareness campaign entitled "Obesity is a sick person's problem" from a year ago was "in line with the framework applicable to communications relating to human health". According to a French study published in 2024, around 18 percent of the French population - equivalent to some ten million people - are obese.

NBC News
Apr 14th, 2026
FDA requests more safety data from Lilly on weight loss pill Foundayo

The FDA is requesting additional safety data from Eli Lilly for its weight loss pill Foundayo, including information on potential heart and liver problems, according to the approval letter published Tuesday. The agency wants more data on risks including heart attacks, strokes, drug-induced liver injuries and delayed stomach emptying. Foundayo, approved this month under a fast-track pilot programme, is the second oral GLP-1 to reach market after Novo Nordisk's Wegovy pill. The FDA is also asking Lilly to collect thyroid cancer risk data for at least 15 years. The requests are considered routine for newly approved drugs, particularly for orforglipron, Foundayo's active ingredient, which has less safety data than older GLP-1s. Lilly must also establish registries tracking children with obesity and pregnancy outcomes.

PR Newswire
Apr 14th, 2026
Vasa Therapeutics partners with Lilly TuneLab to accelerate AI-driven CAMKII inhibitor development

Vasa Therapeutics, a clinical-stage biopharmaceutical company, has partnered with Eli Lilly to use Lilly TuneLab, an AI-enabled drug discovery platform that provides access to models trained on Lilly's proprietary research data. Vasa will use the platform to accelerate development of its CAMKII delta inhibitor, which is planned for Phase 1 clinical trials in 2027. The company's VS-041 is currently in a proof-of-mechanism trial for heart failure, whilst VS-214 is on track for first-in-human trials in 2026. The platform uses federated learning, allowing companies to access Lilly's AI models whilst maintaining data privacy. Vasa will contribute its own experimental datasets to support the platform's improvement. The company focuses on developing therapies for cardiovascular, neuromuscular and age-related disorders.